Jill Leversage is Director at Aurinia Pharmaceuticals Inc. (AUPH). They have made 5 open-market trades across 1 company since 2021, most recently 2024-11-21.
CIK 0001837374
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $85K since 2021, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AUPH | 25,053 | $429K |
Shares reported on the most recent Form 4, priced at the 2024-11-25 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AUPH | SELL | 2024-05-21 | 2024-05-22 | $5.74 | $32K | -5.0% | -0.4% | +15.9% |
| AUPH | SELL | 2023-05-23 | 2023-05-23 | $11.26 | $108K | -11.4% | -14.8% | -14.6% |
| AUPH | BUY | 2021-12-13 | 2021-12-15 | $20.04 | $32K | +19.3% | +0.8% | -46.4% |
| AUPH | BUY | 2021-05-11 | 2021-05-12 | $10.96 | $27K | +8.7% | +10.5% | +30.9% |
| AUPH | BUY | 2021-01-29 | 2021-02-02 | $16.03 | $26K | -2.7% | -17.2% | -22.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.